

Clinical Care Session of the 2026 Annual Cure SMA Research and Clinical Care Meeting

Continuing Medical Education Information

General Information

- Cure SMA Clinical Care Session
- Wednesday June 24th, 2026 at Disney's BoardWalk Inn Hotel in Orlando, FL
- Jointly provided by Postgraduate Institute for Medicine and Cure SMA
- This activity is supported by an independent educational grant from Genentech and Novartis

Target Audience

- This activity is intended for healthcare professionals engaged in the care of patients with Spinal Muscular Atrophy.

Educational Objectives

After completing this activity, the participant should be better able to:

Clinical Care Session Goals include:

- Creating a collaborative platform for healthcare providers from any discipline to exchange knowledge and expertise to advance SMA clinical care.
- Facilitating partnerships and mentorship between emerging clinicians and established leaders in SMA to foster innovative research and the implementation of best practices in SMA care across healthcare organizations.
- Promoting collaborative, multidisciplinary approaches to enhance care and improve quality of life, while promoting collaboration with individuals with SMA, their families, and industry partners.

Points of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The PIM planners and others have nothing to disclose. The Cure SMA planners have nothing to disclose.

Disclosures Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated

according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

The PIM planners and others have nothing to disclose. The Cure SMA planners have nothing to disclose.

Faculty Disclosures

Al Freedman, PhD

Speakers Bureau/Honoraria for non CME: Kyowa Kirin, Arrowhead Pharmaceuticals

Consultant/Advisory Board: Scholar Rock, Novartis, Biogen, NMD Pharma, Amgen, Pharmaessentia, PTC Therapeutics, Amicas, Argenyx

Charlotte Sumner, MD

Grant/Research Support: Biogen, Actio, Biosciences

Speakers Bureau/Honoraria for non-CME: Biogen, Argenx

Consultant/Advisory Board: Roche, Novartis, Biogen (Consultant and IDMC member), Scholar Rock

Tom Crawford, MD

Grant/Research Support: Biogen, Scholar Rock, Sarepta

Consultant/Advisory Board: Scholar Rock

Crystal Proud, MD

Grant/Research Support: Biogen, Biohaven, Genentech, Insmad, ML Bio Solutions, Novartis Gene Therapies, PTC, Pfizer, Regenx Bio, Roche, Sarepta, Solid Biosciences, Scholar Rock

Speakers Bureau/Honoraria for non-CME: Biogen and Italfarmaco

Consultant/Advisory Board: Biogen, Italfarmaco, Sarepta, ML Bio Solutions, Novartis Gene Therapist, Genentech/Roche and Scholar Rock

John Brandsema, MD

Grant/Research Support: Alexion, Argenx, Novartis, Biogen, Biohaven, Catalyst, CSL, Behring, Dyne, Genentech/Roche, Italfarmaco, Janssen, Octapharma, Pfizer, PTC Therapeutics, RegenxBio, Sarepta, Scholar Rock, Solid

Consultant/Advisory Board: Alexion, Argenx, Audentes, AveXis, Novartis, Biogen, Catalyst, CSL Behring, Dyne, Edgewise, Engrada, Genentech/Roche, ITF, Janssen, Mesoblast, NS

Richard Finkel, MD

Grant/Research Support: Biogen, Genentech/Roche, Novartis, Scholar Rock (contract support to institution) Sponsored research agreement from Genentech to institution to support research project

Consultant/Advisory Board: Biogen, Genentech/Roche, Novartis, Scholar Rock, Argenx

Patient Holder/Royalties paid to you: Children's Hospital of Philadelphia- licensing fees, Elsevier publishing Royalties

Anna M Banc-Husu, MD

Grant/Research Support: Mirum Pharmaceuticals

Sarah Wright, DO

Speakers Bureau/Honoraria for non-CME: Sarepta, Genentech, DYNE Therapeutics, Regenx Bio, Biogen

Tina Duong, MPT, PhD

Grant/Research Support: Biogen

Speakers Bureau/Honoraria for non-CME: Scholar Rock, Novartis, Roche

Consultant/Advisory Board: Trinds, Scholar Rock, Novartis, Dyne, Pepgen, Juvena

Perry Shieh, MD

Grant/Research Support: Astellas, Sarepta, Pfizer, Solid, Novartis, PTC Therapeutics, Biogen, EpiCrispr Bio, Dyne, Arthex, Avidity, Edgewise, Amo Pharma, NMD Pharma, Abcuro, Arcellx, Cartesian

Speakers Bureau/Honoraria for non-CME: Biogen, Novartis, Roche, Argenx, Alexion, UCB, Catalyst, Grifols, CSL Behring, Amgen, Johnson & Johnson

Pharma, Percheron, PTC, RegenxBio, Sarepta, Scholar Rock, Solid, Takeda, WaVe

Consultant/Advisory Board: Sarepta, Biogen, Novartis, Roche, Argenx, Alexion, UCB, Catalys, Grifols, CSL Behring, Amgen, Johnson & Johnson

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Cure SMA. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Up to 5.25 hours of CME will be available through the following:

Physician Continuing Medical Education (pending)

The Postgraduate Institute for Medicine designates this CME activity for a maximum of 5.25 ~~0.5~~ *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education (pending)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.25 contact hours.

Continuing Pharmacy Education (pending)

Postgraduate Institute for Medicine designates this continuing education activity for 5.25 contact hours ~~0.5~~ (.525 CEUs) of the Accreditation Council for Pharmacy Education.

UAN JA4008162-9999-26-178-L99-P

Continuing Dietician Education (pending)

This program offers 5.25 CPEUs for dietitians.

Interprofessional Continuing Education (pending)



This activity was planned by and for the healthcare team, and learners will receive 5.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Americans with Disabilities Act (required for live meetings only)

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Jennifer Deans prior to the live event at SMARCC@curesma.org.

Fee Information

No Fee.